Spirea
8 employees on LinkedIn · 2 known investors
Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases. The company develops proprietary linker-payloads and offers ADC design and conjugation expertise for partnering with pharmaceutical and biotech companies.
Founders & leadership
MO
Myriam OuberaiFounder
BR
Bo Rode HansenExecutive Director
Investors · 2
Frequently asked questions
- What does Spirea do?
- Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases. The company develops proprietary linker-payloads and offers ADC design and conjugation expertise for partnering with pharmaceutical and biotech companies.
- Who founded Spirea?
- Spirea was founded by Myriam Ouberai.
- Who are Spirea's investors?
- Spirea's investors include Cambridge Angels group, Start Codon.